Sorafenib i srodni spojevi - inhibitori kinaza u liječenju karcinoma

Professional paper - Professional paper

• Author: Josipa Vidović
• Author: Tomislav Ubrekić
• Author: Diana Lović
• Author: Maja Beus
• Author: Zrinka Rajić Džolić
• Author's institution: University of Zagreb; Faculty of Pharmacy and Biochemistry; (Department of medicinal chemistry)
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Pharmacy; Pharmacy

Abstract (english)

Sorafenib is a relatively new antitumour drug, approved in 2005. It exerts its
antiproliferative action through inhibition of MAPK signalling pathway, inhibition
of angiogenesis and induction of apoptosis. Rationale design of sorafenib started at
the end of the last century, by testing more than 200.000 compounds. Structural
modifications of the found lead compound resulted in the synthesis of sorafenib.
Registered analogues of sorafenib are also described - regorafenib, vemurafenib and
dabrafenib, as well as RAF265, which is still in clinical trials.

• Keywords (croatian): sorafenib; regorafenib; vemurafenib; dabrafenib; hepatocelularni karcinom; karcinom bubrežnih stanica
• Language: croatian
• Publication type: Professional paper - Professional paper
• Publication status: Published
• Peer review: Peer review - domestic
• Publication version: Published version
• Journal title: Farmaceutski glasnik
• Numbering: vol. 70, no. 9, pp. 577-586
• p-ISSN: 0014-8202
• URN:NBN: urn:nbn:hr:163:956425
• Publication: 2014
• Type of resource: Text
• Access conditions: Open access
• Created on: 2020-10-02 14:12:52